1

CURRICULUM VITAE 08/09/2010

NAME: OLIVERA (OLJA) J. FINN, Ph.D. BIRTH DATE: November 2, 1949 HOME ADDRESS: 150 North Woodland Road BIRTH PLACE: Pirot, Yugoslavia Pittsburgh, PA 15232 CITIZENSHIP: U. S. A HOME PHONE: (412) 661-9902 BUSINESS ADDRESS: Department of Immunology University of Pittsburgh School of Medicine,

Room E1044 Biomedical Science Tower, Pittsburgh, PA 15261 USA

BUSINESS PHONE, FAX, EMAIL: (412) 648-9816, (412) 648-7042, ojfinn@pitt.edu ------------------------------------------------------------------------------------------------------------------

EDUCATION AND TRAINING

Undergraduate Dates Attended Name and Location Degree Received Major of Institution and Year Subject 1969-1972 Inter-American University B.S. - 1972 Biology

Puerto Rico

Graduate Name and Location Degree Received Major Professor of Institution and Year and Discipline 1975-1980 Stanford University Ph.D. - 1980 Immunology/Virology Stanford, CA Dr. H. S. Kaplan Post Graduate Name and Location Name of Program Director of Institution and Discipline 1979-1982 Stanford University Dr. Ronald Levy Division of Oncology Immunology/Oncology Dept. of Medicine Stanford, CA

2

ACADEMIC APPOINTMENTS AND POSITIONS Years Inclusive Name and Location of Institution Title or or Organization Position/Rank 2009-present University of Pittsburgh Distinguished Professor School of Medicine and Chair Department of Immunology 2002 - 2009 University of Pittsburgh Professor and School of Medicine Chair Department of Immunology 1995 - 2002 University of Pittsburgh Professor School of Medicine Department of Molecular Genetics and Biochemistry 1996 - present University of Pittsburgh Professor School of Medicine (secondary appoint.) Department of Surgery 1991-1995 University of Pittsburgh Associate Professor School of Medicine Department of Molecular Genetics and Biochemistry 1991-1996 University of Pittsburgh Associate Professor School of Medicine (secondary appoint.) Department of Surgery 199l - present University of Pittsburgh Cancer Institute Immunology Program Leader 1985-1991 Duke University Medical Center Assistant Professor Department of Microbiology & Immunology 1982-1984 Duke University Medical Center Research Assistant Department of Microbiology & Immunology Professor

HONORS AND AWARDS

Year Title of Award 2009 Mentor of the Year, Biomedical Graduate Student Association, University of Pittsburgh School of Medicine 2008 President, American Association of Immunologists (AAI)

3

2006 Women Driving the Material World Award, Women and Girls Foundation of South West Pennsylvania 2005 Permanent Visiting Professor, University of Florence School of Medicine, Florence, Italy 2004 Honorary Professorship, Fourth Military University, Xi’an, PRC 2002 Woman of Distinction Award, Girl Scouts of Western Pennsylvania 2002 Joseph S. Ingraham Classical Immunology Lecturer Award 1997 Pendelton Distinguished Lecturer, Massey Cancer Center, MCV 1997 Mentor of the Year, Survival Skills & Ethics Program, University of Pittsburgh 1991-1996 Faculty of the American Cancer Society 1996 University of Pittsburgh Chancellor's Distinguished Research Award 1994 Pittsburgh Cancer Institute Scientific Leadership Award 1994 Outstanding Faculty Award, Department of Molecular Genetics and Biochemistry 1994 Distinguished Lecturer, Jonsson Comprehensive Cancer Center, UCLA 1989 NATO Senior Guest Fellow, National Research Council, Milano, Italy 1984 Leukemia Society of America, Special Fellow 1982 NATO Advanced Study Institute Fellow 1981 WHO Fellow, The Weizmann Institute of Science, Rehovot, Israel 1980 Cancer Biology, PHS Award/Grant No. 5-T32-CA 09302-04 1972 Beta Beta Beta, Biological Honor Society 1972 B.S., Summa cum laude 1969-1972 Academic Honor Scholarship, Inter-American Universit

4

PROFESSIONAL ACTIVITIES

Editorial Boards Senior Editor for Immunology, Cancer Research, 2002-2007 Associate Editor, Cancer Research, 1998-2002 Advisory Editor, Journal of Experimental Medicine, 2003-2007 Associate Editor, Cellular Immunology, 1997-present Associate Editor, Clinical Cancer Research, 1999-2003 Associate Editor, Cancer Prevention Research (CaPR), 2008-present Special Advisor to the Editor in Chief, Cancer Research, 2010-2011 Member, Editorial Board, Immunology and Cell Biology, 2010-2012 Reviewer for many journals Grant reviews Special Member, NIH Experimental Immunology Study Section, from 1988-1991 Member, NIH Experimental Immunology Study Section, 1992-1996 Member, NCI Subcommittee C, 1998-2002 Member, Scientific Review Board, The V-Foundation for Cancer Research, 2005-present Member, Susan G. Komen, Cure’s Immunotherapies Scientific Peer Review Committee, 2008-2010 Reviewer, European Research Council, 2009-2013 Council Member, American Cancer Society, 2010-present Professional Societies Member, Sigma Xi, 1974-present Member, American Association for the Advancement of Science, 1982-present Member, The Transplantation Society, 1987-1995

5

Member, American Association of Immunologists, (AAI), 1980-present Member, Public Affairs Committee, American Association of Immunologists (AAI), 1996-1999 and 2001-2003 Elected Councilor, American Association of Immunologists (AAI), 2002-2006 Vice President, American Association of Immunologists (AAI), 2006-2007 President, American Association of Immunologists (AAI), 2008 Elected Councilor, International Union of Immunology Societies (IUIS)-2004-2007, re-elected, 2007-2010 Member, New York Academy of Sciences, 2005-present Member, American Association for Cancer Research, 1990-present Member, Women in Cancer Research, 1994-present Member, AACR Committee on Immunology (Working Group), 2006-present Member, AACR Cancer Immunology Working Group Steering Committee (CIMM), 2008-2011 Scientific Advisory Boards Member, External Scientific Advisory Committee, The Wistar Institute, 1993-present Member, External Scientific Advisory Committee, Colorado Comprehensive Cancer Center, 1996-present Member, External Scientific Advisory Committee, UMass Cancer Center, 1998-present Member, Scientific Advisory Committee, (CanVac), Canadian Vaccines Program, 1999-2006 Member, NCI, Board of Scientific Counselors, 2005-2010 Member, NCI Immune Response Modifiers Pathway Working Group, 2008-present Member, Scientific Advisory Board for Loyola’s Infectious Disease and Immunology Institute, 2009 Member, External Advisory Board, Mayo Clinic SPORE in Ovarian Cancer, 2010-present Seminars and Invited Lectureships Conference Organization and Invited Participation (last 10 years only)

6

Organizer: Keystone Symposium on Cellular Immunity and Immunotherapy of Cancer, January 21-26, 2000, Santa Fe, NM. Invited Chair: Keystone Symposium on Dendritic Cells, March 12-17, 2001, Taos, NM. Invited Speaker: Albert B. Sabin Vaccine Institute Workshop on Cancer Vaccines, March 7-10, 2001, Bahamas Invited Speaker: US/Japan Cancer Panel, March 22-24, 2001, Maui, Hawaii. Invited Speaker: Biologics for Cancer Diagnosis, Prevention and Immunotherapy, April 12-13, 2001, Ames, IA Invited Speaker: Canadian Society for Immunology Annual Meeting,, April 7-11, 2001, Chateau Lake Louise, Lake Louise, CA Invited Speaker: Workshop on Carbohydrates and the Immune Response, August 31-September 2, 2001, Lesbos, Greece Co-Organizer: Asian-Pacific Conference of Tumor Biology, September 16-20, 2001, Beijing, PRC Invited Speaker: International Immunology Conference, March 12-15, 2002, Al Ain, United Arab Emirates Invited Speaker: 7th International Symposium on Dendritic Cells, September 19-24, 2002, Bamberg, Germany Invited Chair: Annual Meeting of the European Network of Immunology Institutes, May 15-19, 2002, Les Embiez, France Invited Chair: EORTC-NCI-AACR 2002 Symposium on Molecular Targets and Cancer Therapeutics, November 19-22, 2002, Frankfurt, Germany Co Chair: Symposium on Dendritic Cells and Control of Immunity, Annual Meeting of the American Association of Immunologists, April 20-24, 2002, New Orleans, LA Invited Speaker: Presidential Symposium on Tumor Immunology, Annual Meeting of the American Association of Immunologists, April 20-24, 2002, New Orleans, LA Invited Speaker: XIV Annual Pezcoller Symposium "The Novel Dichotomy of Immune Interactions with Tumors" May 30-June 1, 2002, Trento, Italy Organizer: US/Japan Workshop on Mucins and Other Glycoproteins in Tumor Progression, Metastasis and Anti-tumor Immune Responses,” January 23-26, 2003, Maui, Hawaii. Organizer: Workshop Chair: Keystone Symposia on “Dendritic Cells and the Cell Biology of the Immune Response,” March 3-10, 2003, Keystone, CO. Invited Speaker: International Workshop on Mucins, April 1-4, 2003, Crete, Greece.

7

Keynote Speaker: International Society for Biologicals, Conference on Therapeutic Cancer Vaccines, April 27-29, 2003, Los Angeles, CA. Co-Chair: Symposium on Tumor Immunity, Annual Meeting of the American Association of Immunologists, May 6-10, 2003, Denver, CO. Invited Speaker: International Conference on Brain Tumors, May 25-28, 2003, Sorento, Italy. Invited Speaker: Annual Meeting of the Society for Reproductive Immunology, June 19-21, 2003, New Heaven, CT Keynote Speaker: Dedication of Dartmouth Cancer Center, October 3, 2003, Rochester, CT. Invited Speaker: MD Anderson Symposium on Cancer Immunity, October 14-17, 2003, Houston, TX Invited Speaker: Rhode Island Hospital Mini-Symposium on Translational Research, November 6-7, 2003, Providence, RI, Invited Speaker: Miami Nature Biotechnology Winter Conference, February 1-4, 2004, Miami, FL Co-Chair: Symposium on “Bridging the Innate and Adaptive Immune Responses”, Annual Meeting of the American Association for Cancer Research, March 27-31, 2004, Orlando FL Invited Speaker American Society of Clinical Oncology Meeting, June 5-7, 2004, New Orleans, LA Co-Chair: Asian-Pacific Conference of Tumor Biology, August 21-24, 2004, Xi’ian, PRC Invited Speaker: Symposium “Tumor Escape and Its Determinants.” October 10-13, 2004, Salzburg, Austria Invited Speaker: 8th International Symposium on Dendritic Cells, October 17-21, 2004, Brugge, Belgium. Invited Speaker: International Cancer Vaccine Symposium, The Royal Society of Medicine, November 12-14, 2004, London, UK Invited Speaker: 4th Midwinter Conference of Immunologists at Asilomar State Park, January 22-25, 2005, San Francisco, CA Invited Speaker: Keystone Symposium on Dendritic Cells at the Center of Innate and Adaptive Immunity: Eradication of Pathogens and Cancer and Control of Immunopathology, February 1-7, 2005, Vancouver, British Columbia, Canada. Invited Speaker: Keystone Symposium, Inflammation and Cancer, February 27-March 3, 2005. Breckenridge, Colorado Workshop Chair: Keystone Symposium, Basic Aspects of Tumor Immunology II, March 19-24, 2005, Keystone, Colorado.

8

Co-Chair: 96th Annual Meeting of the American Association for Cancer Research, April 16-20, 2005, Anaheim, CA Invited Speaker: The 3rd Congress of the Federation of Immunology Societies of Asia-Oceania, April 18-22, 2005, Shanghai, China. Invited Speaker: NY Academy of Sciences Workshop on Human Immunology: Patient Based Research, May 16-18, 2005, New York, NY. Invited Speaker: Bio 2005, June 20-22, 2005, Philadelphia, PA Invited Speaker: Translational Immunology Related to Cancer, September 22-23, 2005, NIH, Bethesda, MD Co-Chair: First International Conference on Immune-Mediated Diseases: “From Theory to Therapy”, October 3-8, 2005, Moscow Russia Invited speaker: Institute of Molecular Oncology Foundation, (IFOM), November 4-6, 2005 Milano, Italy Invited Speaker: Novartis Foundation Symposium “Innate Immunity to Pulmonary Infection” November 28-30, 2005, Capetown, South Africa Invited Speaker: UCSF Comprehensive Cancer Center Symposium: “Inflammation and Cancer: Bench to Bedside, January 18, 2006, San Francisco, CA Invited Speaker: The 2006 Midwinter Conference of Immunologists at Asilomar State Park, January 28-31, 2006, Big Bear Lake, CA Invited Speaker: International Cancer Vaccine Symposium, February 5-7, 2006, Washington, DC Invited Speaker: The Weizman Institute of Science Symposium, March 12-18, 2006, Rehovot, Israel Invited Speaker: Annual Meeting of the African Immunology Societies, March 20-23, 2006, Dakar, Senegal, Africa Invited Speaker: UM/Sylvester Cancer Center Distinguished Speaker Lecture Series in 2006, March 30-31, 2006, Miami, FL Invited Speaker: 2nd IFOM-IEO International Meeting on Cancer, May 5-8, 2006, Milan, Italy Invited Participant: C-Change Cancer Prevention Research Summit, June 12-13, 2006, Bethesda, MD Invited Speaker: 6th International Dresden Symposium on Immunotherapy of Cancer, September 21-23, 2006, Dresden, Germany Invited Speaker: Fifth Annual AACR Conference on Frontiers in Cancer Prevention Research, November 12-15, 2006, Boston, MA

9

Co-Organizer: AACR Special Conference on Tumor Immunology: An Integrated Perspective, November 29-December 2, 2006, Miami, FL Invited Speaker: Keystone Symposium “Immunological Intervention in Human Disease,” January 6-11, 2007, Big Sky, Montana (Session Chair) Invited Speaker: Fourth Biennial Meeting on Molecular Targets in Cancer Therapy, January 25-28, 2007, Clearwater, FL Invited Speaker: Gordon Research Conference on Cilia, Mucus and Mucociliary Clearance, February 4-9, 2007, Ventura Beach, CA Invited Speaker: Keystone Symposium on Mechanisms Linking Inflammation and Cancer, February 10-15, 2007, Santa Fe, NM Invited Speaker: AACR Annual Meeting, Symposium “Tumor Immunotherapy,” April 14-18, 2007, Los Angeles, CA Co-Chair: AIDS Vaccine Program site visit, May 1-3, 2007, Frederick, MD Invited Chair: 95th AAI Annual Meeting, “Immunology 2007”, May 18-22, 2007, Miami Beach, FL Invited Speaker: 2007 EMBO Conference, May 7-12, 2007, Capo Caccia, Sardinia, Italy Invited Speaker: Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, Symposium, June 7-11, 2007, San Diego, CA Invited Lecturer: 2007, AAI Advanced Course in Immunology, University of Minnesota, August 4-9, 2007, Minneapolis, MN Invited speaker: 13th International Congress of Immunology, August 21-25, 2007, Rio de Janeiro, Brazil Invited Participant: 2nd International IMD Congress, 2007, September 10-15, 2007, Moscow, Russia Invited Speaker: National Jewish Medical and Research Center, Pixie Campbell Memorial Lecture, September 18-20, 2007, Denver, CO Invited Reviewer: Rapid Access to Intervention Development Program (RAID), October 9-10, 2007, Bethesda, MD Invited Chair: Committee review for Dr. Kenneth Rock, University of Massachusetts Medical School, October 22-23rd, 2007, Worchester, MA Invited Lecturer: International Symposium on Cancer Biology, National Institute of Immunology, November 14-17, 2007, New Delhi, India Invited Reviewer: Sixth Annual AACR International Conference, “Frontiers in Cancer Prevention Research”, December 5-8, 2007, Philadelphia, PA

10

Invited Participant: Eleventh Annual NCI Intramural Scientific Retreat, January 8, 2008, Bethesda, MD, “invited–declined” Invited Lecturer: 1st International Meeting of the Singapore Society of Immunology (SSI), January 14-16, 2008, Biopolis, Singapore. Invited Lecturer: University of Virginia Health System, 2008 Anderson Symposium, April 23-24, 2008, Charlottesville, VA Invited Lecturer: Austrian Society for Allergology and Immunology Annual Meeting, September 4-7, 2008, Vienna, Austria Invited Speaker: 2nd EFIS/EJI Belgrade Symposium/Postgraduate Course: Inflammation at the Interface of Innate and Acquired Immunity, September 7-10, 2008, Belgrade, Serbia Invited Reviewer: University of Iowa Graduate Program in Immunology, September 25-27, 2008, Iowa City, Iowa. Invited Participant: 2nd Mediterranean Clinical Immunology Meeting, October 4-7, 2008, Antalya, Turkey Invited Lecturer: International Cancer Immunology and Immunotherapy Meeting, October 9-11, 2008, Athens, Greece Invited Speaker: Federation of Immunological Societies of Asia-Oceania (FIMSA) Meeting, October 17-20, 2008, Taipei, Taiwan Organizer: 6th International Cancer Vaccine Symposium: Stages of Cancer Vaccine Development October 28-30, 2008, New York, NY Invited Session NCI Translational Science Meeting, November 7-9, 2008, Washington, DC Co-Chair: Chairperson: AACR, Special Conference in Cancer Research on Tumor Immunology: New Perspectives, December 2-5, 2008, Miami, FL Invited Participant: Novartis, Prostate Cancer Vaccine Meeting, December 6-8, 2008, Boston, MA Invited Speaker: 2009 Winter Academy Meeting, February 20-22, 2009, Naples, Florida Invited Participant: Louisiana State University Health Sciences Center COBRE External Advisory Meeting, March 19-20, 2009, New Orleans, LA Co-Chair: AACR, 100th Annual Meeting, 2009, April 18-22, 2009, Denver, Colorado Invited Participant: NCI Vaccine Branch site visit, April 27-29, 2009, Bethesda, MD Invited Speaker: The 96th Annual Meeting of the American Association of Immunologist, May 7-12, 2009, Seattle, WA

11

Invited Speaker: Cancer Vaccine Meeting, Universidad Nacional de Quilmes, June 1-5, 2009, Buenos Aires, Argentina Program Co-Chair, Federation of Clinical Immunology Societies (FOCIS) Meeting, June 11-15, 2009, San Francisco, California. Invited Speaker: 2009, SFB 415 International Meeting, September 10-12, 2009, Hamburg, Germany Invited Speaker International Meeting in Sofia, Bulgaria, October 7-15, 2009. Invited Speaker: Federation of African Immunology Societies (FAIS) Congress, November 6-11, 2009,

Sharm El-Sheik, Egypt Invited Speaker: Cold Spring Harbor Laboratory Meeting on Harnessing Immunity to Prevent and Treat Disease, November 11-14th, 2009, Cold Spring Harbor, NY Invited Speaker: The Nobel Forum, Karolinska Institutet “Frontiers in Cancer Research Symposium”, March 11-12th, 2010, Stolkholm, Sweden. Invited Participant: NBCC Catalyst Meeting: Prophylactic Breast Cancer Vaccines, Calistoga, CA, March 20-22, 2010 Session Chair: AACR, 101st Annual Meeting, 2010, “Conquering Cancer Through Discovery Research” The Educational Session, “Immunology 101”, April 17-21st , 2010, Washington, DC Invited Speaker: AAI 97th Annual Meeting, “Immunology 2010, May 7-11, 2010, Baltimore, MD Session Chair: Federation of Clinical Immunology Societies Meeting, “Keynote Session-Keynote Symposia” June 24-28, 2010, Boston, MA Invited Participant: Cancer Molecular Therapeutics Research Conference, July 18-22, 2010, Princeton University, Princeton, NJ Workshop Chair: 14th International Congress of Immunology, August 22-27, 2010, Kobe, Japan Invited Speaker: Annual Buffalo Conference on Immunology, September 13-14, 2010, Niagara Falls, New York Session Chair 11th Annual International Symposium on Dendritic Cells “DC2010: Forum on Vaccine Science,” September 26-30, 2010, Lugano, Switzerland Invited Speaker: 10th International Conference “Progress in Vaccination Against Cancer”, September 27-30, 2010, Cambridge, UK Invited Speaker: 4th Vaccine and ISV Annual Global Congress, October 3-6, 2010, Vienna, Austria. Invited Speaker: The Brazilian Immunology Meeting, November 3-6, 2010, Porto Alegre, Brazil Invited Participant: 9th International Workshop –Immunotherapy 2010: Rupture and Restoration of

12

Self Tolerance, November 15-19. 2010, Havana, Cuba Invited Speaker: 2011 Keystone Symposium on New Frontiers at the Interface of Immunity and Glycobiology, March 6-11, 2011, Alberta, Canada Invited Speaker: First Prophylactic Cancer Vaccine Conference, March 16-18, 2011, Tempe, Arizona. Invited Seminars (2000-present only) 2001 New York University, NY, host, Dr. Thornbecke. 2001 University of Texas Southwestern Medical School, Dallas, TX, host, Dr. Vitetta. 2001 Karmanos Cancer Institute, Detroit, MI. 2001 Duke University MD/PhD Program, Durham, NC, host, Dr. Pizzo. 2001 Wake Forest University, Winston Salem, NC, host, graduate students, Cancer Biology Program. 2001 Roswell Park Memorial Institute, Buffalo, NY, hosts, Drs. Mihich and Ferrone. 2002 University of South Carolina School of Medicine, Charleston, host, Dr. Thomlinson. 2002 M.D. Anderson Cancer Center, host, Dr. Hortobagyi. 2003 University of Minnesota Cancer Center, Minneapolis, MN, host, Dr. Chen. 2003 Chiron Corporation, San Francisco, CA, host, Dr. Fente. 2003 Ohio State Medical Center, Columbus, Ohio, host, Dr. Caliguiz. 2003 The Chicago Medical School, Chicago, IL, host, Dr. Kim. 2003 UT MD Anderson Cancer Center, Houston, TX. 2003 University of California, Irvine, host, Dr. Grottman. 2004 City of Hope, Los Angeles, CA, host, Graduate students. 2004 University of Miami School of Medicine, Miami FL, host, Dr. Lopez. 2004 Moffit Cancer Center, Tampa, FL, host, Dr. Mulé. 2004 I.R.B.M.P., Merck Research Laboratories, Rome, Italy, host, Dr. Scarselli. 2005 Harvard University, host, Dr. Laurie Glimsher.

13

2005 University of Milano-Bicocca, Milano, Italy, host, Dr. Paola Castagnoli. 2005 University of Florence, host, Dr. Romagnani. 2006 Rockefeller University, New York, NY, host, Dr. Madhav Dhodapkar. 2006 LSU Health Sciences Center, New Orleans, LA, host, Dr. John Estrada. 2007 NYU Cancer Institute, New York, NY, host, Dr. Burakoff. 2007 UCSF, Immunology Graduate Program, San Francisco, CA, host Dr. Lewis Lanier. 2007 NIH/NCI, Frederick, MD, host, Dr. Zack Howard. 2007 University of Massachusetts Medical School, Worcester, MA, host, Dr. Judith Ockene. 2007 University of Pittsburgh School of Medicine, Department of Pathology. 2008 UCLA, Dept. of Microbiology, Immunology and Molecular Genetics, host, Dr. Jeffrey Miller. 2008 University of Pittsburgh, Clinical and Translational Science Institute, host, Dr. Jennifer Grandis. 2008 University of Pittsburgh, Office of Academic Development panelist, host Joan Lakowski 2008 Trudeau Institute, Saranac Lake, NY, host, Dr. Richard Dutton. 2009 University of Pennsylvania, Immunology Colloquim, Philadelphia, PA, host, Dr. Mark Greene 2009 NCI Laboratory of Experimental Immunology Grand Rounds, Bethesda, MD, host, Dr. Robert Wiltrout 2009 Arizona State University, The Biodesign Institute, host, Dr. Stephen Johnston 2009 University of Pittsburgh, Professional Development Course, Mock study section, Chair 2009 University of North Carolina, Raleigh Durham, NC, host, Dr. Ting 2009 University of Alabama at Birmingham, Birmingham, AL, host, Dr. Ada Elgavish 2010 The Jefferson Vaccine Center of Thomas Jefferson University, Philadelphia, PA, host, Dr. Scott Waldman 2010 Fox Chase Cancer Center, Distinguished Lecturer Series, Philadelphia, PA, host, Dr. Hayakawa 2010 University of Pittsburgh, Office of Academic Career Development workshop, panelist 2010 Cancer Institute of New Jersey, Cancer Center Grand Rounds, New Brunswick, NJ. host, Dr. Edmund Lattime.

14

2011 Karmanos Cancer Institute Grand Rounds Seminar Series, Detroit, Michigan, host, Dr. Wei-Zen Wei 2011 University of Toronto, Toronto, ON, Canada, host, Dr. Michelle Letarte Teaching and Training Past Trainees: M. Carrie Miceli, PhD., Graduate student 1983-1988. Ph.D. awarded in May, 1988 at Duke University. Present Position: Professor, Department of Microbiology and Immunology, University of California, Los Angeles. Donna L. Barnd, PhD., Graduate student 1985-1990. Ph.D. awarded in May, 1990 at Duke University. Present position: Patent Examiner, US Patent Office, Washington DC. Derek A. Persons, MD/PhD., Graduate student 1984-1990. Ph.D. awarded in August, 1990 at Duke University. Present position: Professor, Department of Medicine, Hematology/Oncology, St. Jude’s Hospital, Memphis, TN. Nancy S. Schek, PhD., Postdoctoral fellow 1986-1988. Present position: Research Associate, Department of Medicine, University of Pennsylvania School of Medicine. Lindsey A. Kerr, MD., Stead Fellow 1984/85 and postdoctoral fellow 1986-87. Present position: Professor, Department of Urology, Mayo Clinic. Bruce D. Gitter, PhD., Postdoctoral Fellow 1983-1984. Present position: Senior Scientist, Eli Lilly and Co., Indianapolis, IN. Susan Hand, PhD., Graduate student 1986-1992. Ph.D. awarded in September, 1992 at Duke University. Present position: Staff Scientist, Fred Hutchinson Cancer Center, Seattle, WA. Bruce Lee Hall, MD/PhD Graduate student 1986-1991. Ph.D. awarded in July, 1991 at Duke University. Present position: Professor, Department of Surgery, Washington University, St. Louis, MS. Keith Jerome, MD/PhD., Graduate student 1987-1992. Ph.D. awarded in July, 1992 at Duke University. Present position: Associate Professor, Pathology, University of Washington School of Medicine, Seattle, WA. Allan Kirk, MD/PhD., Graduate student from 1989-1992. Ph.D. awarded in September, 1992 at Duke University. Present position: Professor of Surgery and Scientific Director, The Emory Transplant Center, Emory University, Atlanta, GA. Elisabeth Schweins, Masters degree student from the Max Planck Institut, Berlin, 1990-1991, MS degree awarded in March, 1991. Present Position: unknown.

15

Maha Atwa Ibrahim, MD., Postdoctoral Fellow, Asuit University Medical School, Asuit, Egypt, 1990-1991, degree awarded in June, 1991 in Egypt. Present Position: unknown. Dawen Bu, MD/PhD, Postdoctoral fellow 1990-1993. Research Associate, 1993-1995, Department of Gastroenterology, Saint Justine Hospital, University of Montreal, Montreal, Canada. Present position unknown. J. Darrell Fontenot, PhD., Postdoctoral Fellow 1992-1993. Last known position: Research Scientist, Theoretical Biology, Los Alamos National Laboratory, Los Alamos, NM. Yasuo Kotera, PhD., Postdoctoral Fellow 1992-1993. Present Position: Senior Scientist, Kanebo, Inc., Osaka, Japan. Gabriele Pecher, MD., Postdoctoral fellow 1992-1994. Present Position: Clinician/Scientist, Max Plank Institut, Berlin, Germany. Yasuyuki Kirii, PhD., Postdoctoral Fellow 1993-1994. Present Position: Senior Scientist, Kanebo, Inc., Osaka, Japan. Nieves Domench, PhD., Postdoctoral Fellow 1992-1995. Present position: Senior Scientist, CSIA Research Institute, Madrid, Spain. Robert Henderson, PhD., Postdoctoral Fellow 1993-1996. Last known position: Senior Staff Scientist, Corixa Corporation, Seattle, WA Julie Magarian-Blander, PhD., Graduate student 1991-1997. Ph.D. awarded in September 1997. Present Position: Assistant Professor of Immunobiology, Mount Sinai School of Medicine, New York, NY. Mark Alter, MD/PhD, Graduate student 1992-1997. Ph.D. awarded in April 1998. Research Fellow, Department of Neurobiology and Behavior, College of Physicians and Surgeons, Columbia University, New York, NY. Present Position: Clinical Associate, Center for Neurobiology and Behavior, University of Pennsylvania, Philadelphia, PA Simon Barratt-Boyes, D.V.M., Ph.D., Postdoctoral Fellow 1994-1998. Present Position: Associate Professor, Department of Microbiology and Infectious Diseases, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. Ira Bergman, MD/PhD, Graduate student 1994-1998. Present Position: Professor of Neurology, Department of Pediatrics and Neurology, Children’s Hospital of Pittsburgh, Pittsburgh, PA. James Snyder, PhD., Graduate student 1993-1999. Ph.D. awarded in August 1999. Present Position: Scientific Review Officer, NIH. Elizabeth Hiltbold, PhD., Postdoctoral Fellow 1996-1999. Present Position: Associate Professor, Department of Microbiology and Immunology, Wake Forest University, Winston Salem, NC. Jan Schmileau, MD/Ph/D., Postdoctoral Fellow 1997 to 2000. Present Position: Associate Professor, University Clinic, Department of Oncology, Bochum, Germany.

16

Melina Soares, PhD., Graduate student 1995 to 2001. Ph.D. awarded in April 2001. Present Position: Asst. Professor, Dept. of Pharmacology, UT Southwestern Medical School, Dallas, TX. Henry Kao, PhD., Graduate student 1996 to 2001. Ph.D. awarded in April 2001. Present Position: Research Scientist, Allergan, Inc., Irvine, CA Pawel Ciborowski, PhD., Research Associate 1994 –1999. Instructor 1999-2001. Present Position: Assistant Professor of Biochemistry and Molecular Biology, Director, Proteomics Program, University of Nebraska Medical Center, Omaha, NE. Daniel Graziano, PhD., Postdoctoral Fellow, 2000-2003. Present Position: Technical Sales Consultant, Miltenyi Biotec, Pittsburgh, PA. Anda Vlad, MD/PhD., Graduate student, 1997 to 2002. Ph.D. awarded in April 2002. Present Position: Assistant Professor, Department of OB-GYN, Magee Women’s Research Institute, Pittsburgh, PA. Jessica Candelora, MD/PhD, .Graduate student, 1999 to 2003. Ph.D. awarded in August 2003. Present Position: Child Psychiatry Fellow, University of Pittsburgh Medical Center (UPMC) Pittsburgh, PA. Nehad Alajez, PhD., Graduate student, 2000 to 2003. Ph.D. awarded in December 2003. Present Position: Senior Postdoctoral Fellow, Ontario Cancer Institute, University Health Network, Toronto, Canada. Hiroyuki Suzuki, MD./PhD., Postdoctoral Research Associate, 2002- 2004. Present Position: Staff Surgeon, Fukushima Medical University, Japan. Casey Carlos, MD/PhD., Graduate student, 2001 to 2005. Ph.D. awarded in June, 2005. Graduated medical school, May, 2007. Present Position: Dermatology Residency, University of Pennsylvania, Philadelphia, PA. Min Yu, MD., Research Associate, 2000 to 2005. Present Position: Research Scientist, Health Science Communications, New York, NY. Michael Turner, PhD., Graduate student researcher, 2000 to 2005. Ph.D. awarded in November 2005. Present Position: Postdoctoral Research Associate, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Pamela Beatty, PhD., Graduate student researcher, 2003-2006. Ph.D. awarded in June, 2006. Present Position: Senior Staff Scientist, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Andy Lepisto, PhD., Postdoctoral Research Associate, 2005-2007. Present Position: Medical Science Liaison, Bristol-Myers Squibb Pharmaceutical Corporation, Pittsburgh, PA. Kira Gantt, PhD., Postdoctoral Scholar, 2004-2007. Present Position: Science Associate, The Journal of Immunology, Bethesda, MD.

17

Xiaochuan Chen, PhD., Postdoctoral Research Associate, 2004-2007. Present Position: Sr. Research Scientist, Center for Molecular Medicine and Immunology (CMMI), Belleville, NJ. Laura Vella, MD/PhD, Graduate student researcher , 2005-2008. Ph.D. awarded in August, 2008. Present Position: Pediatric Residency, University of Chicago, Chicago, IL. . Katja Engelmann, Ph.D., Postdoctoral Research Associate, 2004-2008. Present Position: Research Coordinator, DKFZ, German Cancer Research Center, Heidelberg, Germany. Seung Chul Heo, M.D., Ph.D., Visiting Scholar, 2008-2009. Present Position, Assistant Professor, Department of Surgery, Seoul National University College of Medicine, South Korea. Andreea Negroiu, MD, Postdoctoral Fellow, 2008-2009. Present Position, Fellow, Department of Hematology/Oncology, Boston University School of Medicine, Boston, MA Sean Ryan, PhD., Graduate student researcher, 2004-2009. Ph.D. awarded in July, 2009. Present Position: Postdoctoral Scholar, Case Western Reserve University, Cleveland, OH. Bianca Chen, Health Science Fellow, 2009-2010. Present Position: Medical Student, Duke-NUS Graduate Medical School, Singapore, China. Current Trainees: Sharmila Pejawar-Gaddy, Ph.D., Postdoctoral Research Associate 2006-present Terri Guniperro, MD., Postdoctoral Fellow, 2008-present Sandra Cascio, PhD, Postdoctoral Research Associate, 2008-present Adam Farkas, Graduate Student Researcher, 2009-present Dawn Reichenbach, Graduate Student Researcher, 2010-present Doug Marvel, Graduate Student Researcher, 2010-present Uzoma Iheagwara, Graduate Student Researcher, 2010-present Lixin Zhang, PhD., Visiting Scholar, 2006-present Takashi Kimura, MD, PhD., Visiting Scholar, 2010-present Publications

Refereed Articles

18

1. Acholonu, A.D., and Finn, O.J. (1974) Moniliformis monilliformis (Acanthocephala: moliformidae) in the cockroach Periplanta Americana in Puerto Rico. Trans. Amer. Micros. Soc. 93:141-142.

2. Ricciardi-Castagnoli, P., Lieberman, F., Finn, O.J. and Kaplan, H.S. (1978) T-cell lymphoma

induction by radiation leukemia virus in athymic nude mice. J. Exp. Med. 148:1292-1310. 3. Finn, O.J., Lieberman, M. and Kaplan, H.S. (1978) H-2 antigen expression, loss in vitro,

restoration in vivo, and correlation with cell-mediated cytotoxicity in a mouse lymphoma cell line. Immunogenetics 7:79-88.

4. Lieberman, M., Decleve, A., Ricciardi-Castagnoli, P., Boniver, J., Finn, O.J. and Kaplan, H.S.

(1979) Establishment, characterization, and virus-induced lymphoma of C57Bl/Ka mice. Int. J. Cancer 24:168-177. 5. Finn, O.J., Boniver, J. and Kaplan, H.S. (1979) Induction, establishment in vitro, and

characterization of functional, antigen-specific, carrier-primed murine T-cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 76:4033-4037. 6. Boniver, J., DeCleve, A., Finn, O., Honsik, C., Lieberman, M. and Kaplan, H.S. (1980)

Detection of infectious centers in C57BL/Ka lymphoid cell populations infected in vitro by the radiation leukemia virus. Cancer Res. 40:544-5 .

7. Levy, R., Bergman, Y. and Finn, O. (1981) Hybridoma monoclonal antibodies in the analysis

of human cell surface antigens. In Vitro 17:1051-1057. 8. Hurley, C.K., Nunez, G., Winchester, R., Finn, O., Levy, R. and Capra, J.D. (1982) The human

HLA-DR antigens are encoded by multiple chains loci. J. Immunol. 129:2103-2108. 9. Finn, O.J. and Levy, R. (1982) Multiple HLA-DR antigens: Detection with monoclonal

antibodies and translation in vitro. Proc. Natl. Acad. Sci. U.S.A. 79:2658-2662. 10. Finn, O.J., Stackhouse, C.J. and Metzgar, R.S. (1983) Human Ia beta chains and the invariant

chain share a common antigenic determinant. J. Exp. Med. 158:1344-1349. 11. Metzgar, R.S., Rodriquez, N., Finn, O.J., Lan, M.S., Daasch, V.N., Fernsten, P.D., Meyers,

W.C., Sindelar, W.F., Sandler, R.S. and Seigler, H.F. (1984) Detection of a pancreatic cancer associated antigen (DU-PAN-2) in serum and ascites of patients with adenocarcinoma.

Proc. Natl. Acad. Sci. U.S.A. 81: 5242-5246. 12. Gitter, B.D., Finn, O.J. and Metzgar, R.S. (1985) Cytofluorometric isolation of I937, an Ia+

variant of the human macrophage-like Ia+-cell line, U937. J. Immunol. 134:280-283. 13. Lan, M.S., Finn, O.J., Fernsten, P.D. and Metzgar, R.S. (1985) Isolation and properties of a

human pancreatic adenocarcinoma associated antigen, DU-PAN-2. Cancer Res. 45:305-310. 14. Miceli, C., Metzgar, R., Chedid, M., Ward, F. and O.J. Finn. (1985) Long-term culture and

characterization of alloreactive T-cell infiltrates from renal needle biopsies. Human Immunol. 14:295-304.

19

15. Hollingsworth, M., Rebellato, L., Moore, J., Finn, O. and Metzgar, R. (1986) Antigens expressed on NIH 3T3 cells following transformation with DNA from a human pancreatic tumor.

Cancer Res. 46:2482-2487. l6. Persons, D.A. and Finn, O.J. (1986) A rapid and efficient method for preparing cDNA from

RNA in agarose gel slices. Biotechniques 4:398-403. 17. Bollinger, R.R., Miceli, C., Finn, O.J., McCann, R.L., Seigler, H.F., Stickel, D.L. and

Sanfilippo, F. (1986) Monitoring the donor-specific response of renal transplant patients by needle biopsy and long-term culture of alloreactive T-cell clones. Trans. Proc. XVIII, 748.

l8. Miceli, M.C., Barry, T.S. and Finn, O.J. (1988) Human allograft derived T cell lines: donor class I and class II directed cytotoxicity and repertoire stability in sequential biopsies.

Human Immunol. 22:185-189. 19. Finn, O.J., Miceli, M.C., Sanfilippo, A., Bollinger, R.R. and Barry, T.S. (1988) In vitro and in vivo human T cell repertoire in kidney allograft rejection. Trans. Proc. XX, 155-158. 20. Miceli, M.C., Barry, T.S. and Finn, O.J. (1988) Human renal infiltrating T cells: phenotype-

function correlation and clonal heterogeneity. Trans. Proc XX, 199-201. 21. Kolbeck, P.C., Miceli, M.C., Finn, O.J., Bollinger, R.R. and Sanfilippo, F. (1988) Relationships

among renal allograft biopsy infiltrates, growth of T cell lines, and irreversible rejection. Trans. Proc. XX, 303-305. 22. Barnd, D., Kerr, L., Metzgar, R.S. and Finn, O.J. (1988) Tumor-specific cytotoxic T cell lines

generated from tumor-draining lymph node infiltrate. Trans. Proc. XX, 339-34l. 23. Persons, D.A., Wilkison, W.O., Bell, R.M. and Finn, O.J. (1988) Altered growth regulation and

enhanced tumorigeneicity of NIH/3T3 fibroblasts transfected with a protein kinase C-I cDNA. Cell 52:447-458.

24. Emara, M., Miceli, C., Finn, O.J. and Sanfilippo, F. (1988) Human suppressor T cells induced

in vitro with an autologous renal allograft-derived T cell line. I. Suppressor cell induction, function and specificity. Human Immunol. 23:223-240.

25. Schek, N., Hall, B.L., and Finn, O.J. (1988) Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res. 48:6354-6359. 26. Finn, O.J. and Miceli, M.C. (1989) Effector T cell repertoire selection in human allograft

rejection. Trans. Proc. XXI, 346-348. 27. Miceli, M.C. and Finn, O.J. (1989) T cell receptor beta chain selection in human allograft

rejection. J. Immunol. 142:81-86. 28. Emara, M., Baldwin, M.W., Finn, O.J. and Sanfilippo, F. (1989) A human suppressor T cell

factor that inhibits T cell replication by interaction with the IgM-Fc receptor (CD7). Human Immunol. 25:87-89.

20

29. Emara, M., Finn, O., Baldwin, W.M. and Sanfilippo, F. (1989) Function and specificity of suppressor T-cells and factors derived from a human renal allograft recipient. Trans. Proc. XXI, 36l-364.

30. Barnd, D.L., Lan, M.S., Metzgar, R.S., Finn, O.J. (1989) Specific, MHC-unrestricted

recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86:7l59-7l63.

31. Persons, D.A., Schek, N., Hall Lee, B., and Finn, O.J. (1989) Increased expression of glycolysis-

associated genes in oncogene-transformed and growth-accelerated states. Molec. Carcinogenesis 2:88-94.

32. Emara, M., Finn, O.J. and Sanfilippo, F. (1989) Characteristics of a human liver allograft-

derived T cell line that exhibits suppressor activity. Human Immunol. 26:364-385. 33. Hand, S.L., Hall, B.L. and Finn, O.J. (1990) T cell receptor gene usage and expression in renal

allograft derived T cell lines. Human Immunol. 28:82-95. 34. Stanford, W.L., Strauss, G.H.S. and Finn, O.J. (1990) Drug resistant alloreactive T cells may

contribute to human graft rejection. Transplantation 49:1138-1141. 35. Persons, D.A., Owens, R.D., Ostrowski, M.C. and Finn, O.J. (1991) Protein kinase C expression

mimics phorbol ester-induced transcriptional activation of a murine VL30 enhancer element. Cell Growth and Diff. 2:7-14. 36. Finn, O.J., Persons, D.A., Bendt, K.M., Pirami, L. and Ricciardi, P. (1991) Retroviral

transduction of PKC into CTL clones leads to immortalization with retention of specific function. J. Immunol. 146:1099-1103.

37. Jerome, K.R., Barnd, D.A., Boyer, C.M., Taylor-Papadimitriou, J., McKenzie, J.F.C., Bast, Jr.,

R.C. and Finn, O.J. (1991) Cytotoxic T lymphocytes derived from patients with breast adenocarcinomas recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908-2916.

38. Kirk, A.D., Ibrahim, M.A., Bollonger, R.R., Dawson, D.V. and Finn, O.J. (1992) Renal allograft

infiltrating lymphocytes: A prospective analysis of in vitro growth characteristics and clinical relevance. Transplantation 53:329-338.

39. Hall, B.L. and Finn, O.J. (1992) T cell receptor V gene usage in allograft-derived cell lines

analyzed by a polymerase chain reaction technique. Transplantation 53:1088-1099. 40. Hand, S.L., Hall, B.L. and Finn, O.J. (1992) T cell receptor V gene usage in HLA-DR1-reactive

T cell populations: predominance of Vb8. Transplantation 54:357-376. 41. Hall, B.L. and Finn, O.J. (1992) PCR-based analysis of the T cell receptor Vb multigene family.

BioTechniques 13:248-258. 42. Jerome, K.R., Bu, D. and Finn, O.J. (1992) Expression of tumor-associated epitopes on Epstein-

Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA. Cancer Res. 52:5985-5990.

21

43. Kirk, A.D., Ibrahim, M.A., Bollinger, R.R., Dawson, D.V. and Finn, O.J. (1992) Renal allograft-infiltrating lymphocytes. Transplanation 53:329-338.

44. Jerome, K.R., Domenech, N. Finn, O.J. (1993) Tumor-specific cytotoxic T lymphocyte clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin cDNA. J. Immunol. 151:1654-1662. 45. Magarian-Blander, J., Domenech, N., Finn, O.J. (1993). Specific and effective T cell recognition

of cells transfected with a truncated human mucin cDNA, Ann. NY Acada. Sci. 690: 231-244. 46. Bu, D., Domenech, N., Lewis, J., Taylor-Papadimitriou, J., Finn, O.J. (1993). Recombinant

vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition. J. Immunother. 14: 127-135.

47. Ioannides, C.G., Fisk, B., Jerome, K.R., Irimura, T., Taylor Wharton, J., Finn O.J. (1993).

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151:3693-3703. 48. Hall, B.L, Hand, S.L, Alter, M.D, Kirk, A.D, Finn, O.J. (1993). Variables affecting the T cell receptor Vb repertoire heterogeneity of T cells infiltrating human renal allografts. Transplant Immunol. 1: 217-227. 49. Fontenot, J.D, Tjandra, N., Ho, C., Montelaro, R.C, Finn, O.J. (1993). Biophysical characterization

of one-, two-, and three-tandem repeats of the human mucin (Muc-1) protein core. Cancer Res. 53: 5386-5394.

50. Fontenot, J.D, Finn, O.J, Dales, N., Andrews, P.C, Montelaro, R.C. (1993). Synthesis of large

multideterminant peptide immunogens using a poly-proline b-turn helix motif. Peptide Res. 6: 330-336.

51. Kotera, Y., Fontenot, J.D, Pecher, G., Metzgar, R.S, Finn, O.J. (1994). Humoral immunity

against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54: 2856-2860.

52. Chen, W., Schweins, L., Cook, S., Finn, O.J., Cheever, M.A. (1994). Transfection of

protein kinase C into tumor specific T cell clones. J. Immunol. 153: 3630-3638. 53. Fontenot, J.D., Mariappan, S.V.S., Catasi, P., Domenech, N., Finn, O.J., Gupta, G.

(1995). Structure of tumor associated antigen containing a tandemly repeated immunodominant epitope. J. of Biomolecular Structure and Dynamics 13: 245-260.

54. Ciborowski, P. and Finn, O.J. (1995). Recombinant epithelial cell mucin (MUC-1)

expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy. Biomed. Pept. Prot. & Nucl. Acids 1: 193-198.

55. Domenech, N., Henderson, R.A., Finn, O.J. (1995). Identification of an HLA-A11-

restricted epitope from the tandem-repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155: 4766-4774.

56. Hand, S.L., Alter, M.D., Finn, O.J. (1995). T cell receptor b-chain repertoires are nonrandomly

22

selected in response to HLA-DR1. Transplantation 61: 1084-1094. 57. Magarian-Blander, J., Hughey, R.P., Klinlough, Poland, P.A., Finn, O.J. (1996) Differential expression of MUC-1 on transfected cell lines influences its recognition by MUC-1 specific T cells.

Glycoconjugate J. 13: 749-756. 58. Pecher, G. and Finn, O.J. (1996). Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected EBV-immortalized

autologous B cells. Proc. Natl. Acad. Sci. USA 93: 1699-1704. 59. Barratt-Boyes, S.M., Henderson, R.A., Finn, O.J. (1996). Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood. Immunology 87: 528-534. 60. Goydos, J.S., Elder, E., Whiteside T.L., Finn, O.J., Lotze, M.T. (1996). A phase I trial

of a synthetic mucin peptide vaccine. J. Surg. Res. 63: 298-304. 61. Henderson, R.A., Nimgauonkar, M., Kemp, A., Robbins, P.D., Watkins, S.C., Ball, T.E., Finn, O.J. (1996). Human dendritic cells engineered to express the human epithelial tumor antigen

mucin (MUC-1) through retroviral transduction and differentiation of stem cells. Cancer Res. 56: 3763-3770.

62. Poland, P.A., Kinlough, C.L., Rokaw, M.D., Magarian-Blander, J., Finn, O.J., Hughey, R.P. (1997) Differential glycosylation of MUC-1 in tumors and transfected epithelial and lymphoblastoid cell lines. Glycoconjugate J. 14: 89-96. 63. Barratt-Boyes, S. M., Watkins, S.C., Finn, O.J. (1997). In vivo migration of dendritic cells differentiated in vitro. A chimpanzee model. J. Immunol. 158: 4543-4547. 64. Jerome, K.R., Kirk, A.D., Pecher, G., Ferguson, W.W., Finn, O.J. (1997). A survivor of

breast cancer with immunity to MUC-1 mucin and lactational mastitis. Cancer Immunol. and Immunother. 43: 355-360.

65. Kirii, Y., Magarian-Blander, J., Alter, M.D., Kotera, Y., Finn, O.J. (1998). Functional and

molecular analysis of T cell receptors used by pancreatic and breast tumor(mucin) specific cytotoxic T cells. J. Immunother. 21: 188-197.

66. Barratt-Boyes, S.M., Kao, H., Finn, O.J. (1998). Chimpanzee dendritic cells derived in vitro

from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. J. Immunother. 21: 142-148. 67. Magarian-Blander, J., Ciborowski, P., Hsia, S., Watkins, S.C., Finn, O.J. (1998). Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC-1. J. Immunol. 160:3111-3120. 68. Henderson, R.A., Konitsky, W.M., Soares, M., Barratt-Boyes, S., Ball, E.D., Robbins, P.D., Finn, O.J. (1998). Construction and characterization of retroviral vector encoding the epithelial cell mucin (MUC-1) for use in gene therapy and immunotherapy. J. Immunother. 21: 247-256. 69. Finn, O.J. and Gendler, S.J. (1998). Mimic 1 of MUC1. Nature Biotechnol. 16: 236-237.

23

70. Hiltbold, E.H., Ciborowski, P., Finn, O.J. (1998). Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 58:.5066-5070. 71. Hiltbold, E.M., Alter, M.A., Ciborowski, P., Finn, O.J. (1999). Presentation of MUC1 tumor

antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cellular Immunol. 194:143-149.

72. Barratt-Boyes, S.M., Vlad, A., Finn, O.J. (1999). Immunization of chimpanzees with tumor

antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clinical Cancer Res. 5:1918-1924.

73. Hiltbold, E.M., Vlad, A.M., Ciborowski, P., Watkins, S.C., Finn, O.J. (2000). The mechanism

of unresponsiveness to ciculating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165:3730-3741.

74. Beatty, P., Hanisch, F.-G., Finn, O.J. and Ciborowski, P. (2001) Biochemical characterization

of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients. Clinical Cancer Res. 7:781-787.

75. Kao, H., Amoscato A., Ciborowski, P., Finn, O.J. (2001). A new strategy for tumor antigen discovery based on in vitro priming of naïve T cells with dendritic cells. Clin. Cancer Res. 7: 773-780.

76. Soares, M., Hanisch F.-G., Finn, O.J., Ciborowski, P. (2001). Recombinant human tumor

antigen MUC1 expressed in insect cells: structure and immunogenicity. Prot. Exp.& Pur. 22: 92-100.

77. Schmielau, J. Nalesnik, M.A., Finn, O.J. (2001). Suppressed T-cell receptor z chain expression

and cytokine production in pancreatic cancer patients. Clin. Cancer Res. 7:933-939. 78. Schmielau, J. and Finn, O.J. (2001). Activated granulocytes and granulocyte-derived hydrogen

peroxide are the underlying mechanisms of suppression of T cell function in advanced cancer patients. Cancer Res. 61:4576-4760 79. Soares, M.M., Mehta, V., Finn, O.J. (2001). Three different vaccines based on the 140 amino

acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1 transgenic mice with different potential for tumor rejection. J. Immunol. 166:6555-6563.

80. Kao H., Marto, J.A., Hoffman, T.K., Shabanowitz, J., Finkelstein, S.D., Whiteside, T.L.,

Hunt, D.F., Finn, O.J. (2001). Identification of cyclin B1 as a shared human epithelial tumor-assciated antigen recognized by T cells. J. Exp. Med. 194: No. 9:1313-1323

81. Yu, M., Zhan, Q., Finn. O.J. (2001). Immune recognition of cyclin B1 as a tumor antigen is

a result of its overexpression in human tumor cells that is caused by non-functional p53. Mol. Immunol. 38: 981-987.

82. Ciborowski, P., Finn, O.J. (2002). Non-glycosylated tandem repeats of MUC1 facilitate

attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins. Clin. & Exp. Metastasis 19: 339-345.

24

83. Vlad, A., Muller, S., Cudic, M., Paulsen, H., Laszlo, O., Jr., Hanisch, F.G., Finn, O.J., (2002). Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to MHC-Class II restricted T cells. J. Exp. Med. 196 No. 11:1435-1446.

84. Correa, I., Plunkett, T., Vlad, A., Mungul, A., Candelora-Kettel, J., Burchell, J., Taylor-Papadimitriou, J., Finn, O.J., (2003). Form and pattern of MUC1 expression on T cells

activated in vivo or in vitro suggests a function in T-cell migration. Immunology 108. 32-41. 85. Hanisch, F., Schwientek, T., Bergwelt-Baildon, M., Schultz, J., Finn, O.J. (2003). O-linked

glycans control glycoprotein processing by antigen-presenting cells: a biological approach to the molecular aspects of MUC1 processing by dendritic cells. Eur. J. Immunol. 33: 3242 -32.

86. Ramanathan, R.K., Lee, K.M., McKolanis, Hiltbold, E., Schraut, W., Moser, A.J., Warnick, E.,

Whiteside, T., Osborne, J., Kim, H., Day, R., Troetschel, M., Finn, O.J. (2005). Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in

resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother., 54, (3) 254-264. 87. Suzuki, H., Graziano, D., Mckolanis, J., Finn, OJ, (2005). T-cell-dependent antibody responses against aberrantly expressed cyclin b1 protein in patients with cancer. Clinical Cancer Res., 11, 1521-1526. 88. Cramer, D.W., Titus-Ernstoff, L., McKolanis, J.R., Welch, W.R., Vitonis, A.F., Berkowitz,

R.S., Finn, O.J. (2005). Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer, Epidemio. Biomarkers & Prev., 14 (5): 1125-31.

89. Alajez, NM, Schmielau, J., Alter, MD, Cascio, M., Finn, OJ, (2005). Therapeutic potential

of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and adaptive immune system through bone marrow transduction and immune reconstitution. Blood, 105 (12); 4583-89.

90. Carlos, C., Dong, H.F., Howard, O.M., Oppenheim, J., Hanisch, F., Finn, O.J., (2005) Human tumor antigen MUC1 is chemotactic for Immature dendritic cells and elicits

maturation but does not promote Th1 type immunity. J. of Immunology, 175 (3):1628-35. 91. Egloff, A.M., Weissfeld, J., Land, S.R., Finn, O.J., (2005). Evaluation of anticyclin B1 serum

antibody as a diagnostic and prognostic biomarker for lung cancer. Annals of the New York Academy of Sciences, 1062, 29-40.

92 Alajez NM, Eghtesad S, Finn OJ. (2006) Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. J Biomed Biotechnol. (2):68091. 93. Saito, H., Dubsky, P., Dantin, C., Finn, OJ., Banchereau, J., Palucka, A., (2006) Cross-priming

of cyclin B1, MUC1 and survin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Research, 8-R65, 1-9.

94. Terry, K., Titus-Ernstoff, L., McKolanis, J., Welch, WR, Finn, OJ., and Cramer, D.W., (2007).

Incessant ovulation, Mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemio. Biomarkers Prev. 16:1, 30-35.

25

95. Turner MS, Cohen, PA, and Finn OJ. (2007). Lack of effective MUC1 tumor antigen specific

immunity in MUC1 transgenic mice results from a T helper/T regulatory cell imbalance that can be corrected by adoptive transfer of wild type Th cells. J. Immunology, 178(5): 2787-93.

96. Beatty, P., Plevy, S.E., Sepulveda, A. R., Finn, OJ. (2007). Cutting Edge: Transgenic expression

of human MUC1 in IL10 ־/־ mice accelerates inflammatory bowel disease and progression to colon cancer. J. Immunology, 179(2):735-39.

97. Engelmann K, Shen H, Finn OJ, (2008). MCF7 side population cells with characteristics of cancer

stem/progenitor cells express the tumor antigen MUC1. Cancer Research; 68(7):2419-26. 98. Lepisto, A., Moser, AJ, Zeh, H., Lee, K., Bartlett, D., McKolanis, JR, Geller, B., Schmotzer, A.,

Potter, D., Whiteside, T., Finn, OJ, Ramanathan, R. (2008). A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Therapy, 6,(B): 955-964.

99. Furr, AE, Ranganathan, S., Finn, OJ., (2008). Aberrant Expression of Muc1 Mucin in Pediatric Inflammatory Bowel Disease. Pediatr Dev Pathol, 13(1):24-31 100. Ninkovic, T., Kinarsky, L., Engelmann, K., Pisarev, V., Sherman, S., Finn, OJ., Hanisch, FG,

(2009). Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Molecular Immunology, 47(1):131-40.

101. Silk AW, Schoen RE, Potter DM, Finn OJ., (2009). Humoral immune response to abnormal

MUC1 in subjects with colorectal adenoma and cancer. Mol. Immunol. 47(1): 52-56. 102. Ryan, SO, Vlad, AM, Islam, K., Garièpy, J., Finn, OJ., (2009). Tumor-associated MUC1

glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem., 390(7):611-18.

103. Chen, X., Gao, W., Gambotto, A., Finn, OJ., (2009). Lentiviral vectors encoding human MUC-1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for

universal and safe cancer immunotherapy. Cancer Immunol Immunother. 58(6):977-87. 104. Vella, L, Yu, M, Fuhrmann, S, El-Amine M., Epperson, DE, Finn, OJ. (2009). Healthy

individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci, 106(33):14010-15.

105. Cheever, MA, Alison, JP, Ferris, AS, Finn, OJ, Hastings, BM, Hecht, TT, Mellman I,

Prindiville SA,Viner, JL, Weiner, LM, Matrisian, LM., (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res, 15(17); 5323-37.

106. Vella, L., Yu, M., Phillips, A., Finn, OJ. (2009). Immunity against Cyclin B1 Tumor

Antigen delays development of spontaneous cyclin B1-positive tumors in p53-/- mice. Ann. N.Y. Acad. Sci, 1174:68-73. 107. Finn, OJ., Edwards, RP, (2009). Human papillomavirus vaccine for cancer prevention.

N. Engl J Med., 361(19):1899-901.

26

108. Kadayakkara, DK, Beatty, PL, Turner, MS, Janjic, JM, Ahrens, ET, Finn, OJ, (2010).

Inflammation driven by overexpression of the hypoglycosylated abnormal mucine (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas, 39(4):510-15

109. Beatty, PL, Narayanan, S, Gariépy, J, Ranganathan, S, Finn, OJ, (2010). Vaccine against

MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer. Prev. Res. 3(4): 438-46

110. Pinheiro, SP, Hankinson, SE. Tworoger, SS, Rosner, BA, McKolanis, JR, Finn, OJ, Cramer,

DW. (2010). Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses’ Health Studies. Cancer Epidemiol Biomarkers Prev. 19(6):1595-601.

111. Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, Hatchette TF,

Finn OJ. (2010). Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control. 21(8):1193-201.

112. Finn, OJ, Bancchereau, J., (2010). Cancer vaccines: The state of the art. Semi Immunol.

22(3):103-04. 113. Ryan, SO, Turner, MS, Garnepy, J., Finn, OJ. (2010). Tumor antigen epitopes

interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 70 (14):5788-96

114. Pejawar-Gaddy S., Rajawat Y., Hilioti Z., Xue J., Gaddy DF, Finn OJ, Viscidi RP, Bossis, I.

(2010). Generation of a tumor vaccine candidate based on conjunction of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother, (epub ahead of print).

Reviews and Book Chapters Reviews 1. Lotze M.T. and Finn, O.J. (1990) Progress in cellular immunology: Implications for immunity to cancer. Immunol. Today 11: 190-193.

2. Finn, O.J. (1992) Antigen-specific, MHC-unrestricted T cells. Biotherapy 4:159-170. 3. Finn, O.J. (1993). Tumor-rejection antigens recognized by T lymphocytes. Curr. Opp. Immunol. 5: 701-708. 4. Finn, O.J. (1994). Tumor-specific immune responses and opportunities for tumor vaccines. Clinical Immunol. Immunopathol. 71: 260-262. 5. Finn, O.J., Jerome, K.R., Henderson, R.A., Pecher, G., Domenech, N., Magarian-Blander, J. Barratt-Boyes, S. (1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines Immunol. Rev. 145: 61-89.

27

6. Henderson, R.A. and Finn, O.J. (1996). Human tumor antigens are ready to fly. Adv. Immunol. 62: 217-256. 7. Finn, O.J., Debruyne, L.A., Bishop, D.K. (1996). TCR repertoire in allograft rejection.

International Rev. Immunol. 13: 187-207. 8. Taylor-Papadimitriou, J. and O. J. Finn (1997). Biology, biochemistry and immunology carcinoma- associated mucins. Immunol. Today 18: 105-107. 9. Finn, O.J., Forni, G. (2002). Prophylactic cancer vaccines. Current Opinion in Immunology, 14,

172-174. 10. Finn, O.J., (2003). Premalignant lesions as targets for cancer vaccines. J. Exp. Med. 198, (11) 1623-1626. 11. Finn, O.J., (2003). Cancer Vaccines: Between the idea and the reality. Nature Reviews/Immunology,

3:630-641. 12. Carlos, C., Finn, O..J., (2004). Prophylactic cancer vaccines: a new vision. Enhancer Biotherapy of Cancer, 2, issue 2. 13. Finn, O.J., (2004). Tumor immunology at the service of cancer immunotherapy. Current Opinion in Immunology, 16, No. 12, 127-129. 14. Finn, O.J., (2005). Bridging the innate and adaptive immune responses against cancer: 95th

AACR Meeting, 2004. Cancer Immunol. Immunother., 54, (3) 287-289. 15. Finn, O.J., (2005). Immune response as a biomarker for cancer detection and a lot more. N Engl Jrl. of Med., 353(12) 1288-90. 16. Egloff, A.M., Vella, L.A., Finn, O.J., (2006). Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Research, 1:66 (1): 6-9 17. Yu, M., Finn, O.J., (2006) DNA vaccines for cancer too. Cancer Immunol. Immunother. 55, (2) 119-130. 18. Finn, O.J, (2007). Human tumor immunology at the molecular divide. J. Immunology, 178 (5): 2615-2616 19. Ryan, SO, Gantt, KR, Finn, O.J., (2007) Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol.;142(3):179-189 20. Silk, A.W, Finn, O.J., (2007). Cancer Vaccines: A promising cancer therapy against all odds. Future Medicine, 3, 299-306. 21. Lu, B., Finn, O.J., (2008). T-cell death and cancer immune tolerance. Cell death and Differentiation, 15, 70-79.

28

22. Pejawar-Gaddy S, Finn O.J., (2008). Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol., 67(2):93-102.

23. Finn, O.J. (2008). Cancer immunology, N England of J of Medicine, 358, 2704-15. 24. Finn, O.J. (2008). Tumor Immunology top 10 list, Immunol Rev, 222: 5-8. 25. Finn, O.J. (2008). Immunological weapons acquired early in life win battles with cancer late in life. J. Immunology, 181 (3), 1589-92. 26. Farkas, A.M., Finn, O.J. (2010). Vaccines based on abnormal self-antigens as tumor-

associated antigens: immune regulation. Seminars in Immunol. 22: 125-131. 27. Guinipero, T., Finn, OJ. (2010). Cancer vaccines: Emphasis on pediatric cancers.

Curr .Pharm Des., 16 (3), 292-99.

Chapters 1. Lieberman, M., Segal, S., Finn, O.J., Zan-Bar, I. and Kaplan, H.S. (1977). Differential effects of radiation leukemia virus infection on the immunobiology of C57BL/Ka mice.

In: International Symposium on Radiation-Induced Leukemogenesis and Related Viruses. (4), pp. 231-246.

2. Finn, O.J., Sung, E., Jones, P., and Levy, R. (1983). Two alpha chains and three beta chains of human Ia antigens. In: IR Genes: Past, Present and Future. pp. 203-213.

3. McKolanis, J.R., Finn, O.J. and Metzgar, R.S. (1983). Characterization of human myelomonocytic antigens using monoclonal antibodies. In: Non-HLA Antigens in Health, Aging, and Malignancy, pp. 145-156.

4. Metzgar, R., Mahvi, D., Borowitz, M., Lan, M., Meyers, W., Seigler, H., and Finn, O. (1985).

DU-PAN-2: A pancreatic adenocarcinoma associated antigen. In: UCLA Symposia on Molecular and Cellular Biology.

5. Finn, O.J., Barnd, D.L., Kerr, L., Miceli, C., Metzgar, R.S. (1989). Specific recognition of

human tumor associated antigens by non-MHC-restricted CTL. In: Human Tumor Antigens and Specific Tumor Therapy, pp. 157-166

6. Jerome, K.R., Barnd, D.A., Boyer, C.M., Taylor-Papadimitriou, J., McKenzie, I.F.C., Bast, Jr.,

R.C. and Finn, O.J. (1990). Adenocarcinoma reactive cytotoxic T lymphocytes recognize an epitope present on the protein core of epithelial mucin molecules. In: Cellular Immunity and Immunotherapy of Cancer, pp. 321-328.

7. Finn, O.J. (1992). Pancreatic tumor antigens: Diagnostic markers and targets for

immunotherapy. In: Important Advances in Oncology: pp. 61-77. 8. Hand, S.L., Hall, B.L. and Finn, O.J. (1993). Association of TCR expression with MHC

recognition. In: Tumor Immunobiology: A Practical Approach: pp. 143-158.

29

9. Ciborowski, P., Konitzki, W.M., Blander, J.M., Finn, O.J. (1998). Screening of anti-MUC-1 antibodies for reactivity with native (ascites) and recombinant (Baculovirus) MUC-1 and blocking MUC-1 specific cytotoxic T-lymphocytes. In: Tumor Biology, pp. 147-152.

10. Ciborowski, P., Hiltbold, E.M., Barratt-Boyes, S., Finn, O.J. (1999). MUC-1 mucin as a tumor

antigen in breast cancer. In Breast Cancer: Molecular Genetics, Pathogenesis and Therapeutics, pp 453-468.

11. Finn, O.J. (2000). Glycoprotein antigens. In: Biologic Therapy of Cancer: Principles and

Practice, pp. 549-556. 12. Ciborowski, P. and Finn, O.J. (2000). Expression of MUC1 in insect cells using recombinant

baculovirus. In: Methods in Molecular Biology, vol. 125, Glycoprotein Methods and Protocols: The Mucins, pp 471-486.

13. McKolanis, J.R. and Finn, O.J. (2000). Analysis of the frequency of MHC-unrestricted MUC1-

specific cytototxic T-cells in periopeheral blood limiting dilution assay. In: “Methods in Molecular Biology,” vol. 125, Glycoprotein Methods and Protocols: The Mucins, pp. 463-470.

14. Finn, O.J. (2001). Assessing the important effector mechanisms in the immune response against

cancer. In: Psychosocial Interventions in Cancer,. pp175-192. 15. Turner, M.S., McKolanis, J.R., Ramanathan, R.K., Whitcomb, D., Finn, O.J., (2003). Mucins

in gastrointestinal cancers. In: Cancer Chemotherapy and Biological Response Molifiers. Annual 21, 259-274.

16. Vlad, A., Kettel,-C., J., Alajez, N, Carlos, C., Finn, O.J. (2004). MUC1 immunobiology: from

discovery to clinical applications. In: Advances in Immunology, vol. 82, 249-293. 17. Vlad, A., Finn, O.J., (2004). Glycoprotein tumor antigens for immunotherapy of breast cancer.

In: Breast Disease, vol. 20, 73-79. 18. Graziano, D., Finn, O.J., (2005). Tumor antigens and tumor antigen discovery, In: Tumor

Immunology and Cancer Vaccines, pp. 89-111. 19. Beatty, P.L., Finn, O.J., (2005). Development of cancer vaccines: Current status. In: Vaccines-Frontiers in Design and Development, pp. 231-254. 20. Vella, L.A., Finn, O.J., (2006). Innate and adaptive immunity in lung cancer, In: Innate Immunity

to Pulmonary Infections, pp. 206-215. 21. Finn, O.J., Salter, R. (2006). Immunology in Pittsburgh, In: Immunologic Research 36, 1-3:1-2. 22. Finn, O.J., (2006). Human tumor antigens, immunosurveillance, and cancer vaccines, In: Immunologic Research 36, 1-3:73-82. 23. Lepisto, A., McKolanis, JR, Finn, O.J., (2007), Cancer immunotherapy: Challenges and

opportunities, In: Cancer Immunotherapy, Immune Suppression and Tumor Growth, pp.167-181.

30

24. Engelmann, K, Finn, OJ. (2008), Tumor antigens as modulators of the tumor microenvironment. In: Innate and Adaptive Immunity in the Tumor Microenvironment. The Tumor Microenvironment, Vol.1, (book chapter no. 5)

25. Finn, OJ., Binder, RJ., Brickner, A., Butterfield, L., Ferris, R., Kalinski, P., Okada, H., Storkus, T.,

Zarour, H. (2009). Human Tumor Antigens as Targets of Immunosurveillane and Candidates for Cancer Vaccines. In: Tumor-Associated Antigens: Identification, Charcterization, and Clinical Applications, ISBN:978-3-52732084.4, chapter 2, pp.23-43

Books, Special Issues 1. "Cellular Immunity and Immunotherapy of Cancer", UCLA Symposia on Molecular and Cellular

Biology, New Series, (M.T. Lotze and O.J. Finn, eds.) Wiley-Liss, Inc., New York, NY, 1990. 2. “Cellular Immunity and Immunotherapy of Cancer,” Supplement to Clinical Cancer Research,

Volume 7, Number 3, O.J. Finn and M.T. Lotze, eds., 2001. 3 3. Immunological Reviews, Tumor Immunity Issue, April, 2008, Finn, O.J. Guest Editor. 4. Seminars in Immunology, Tumor Immunology Issue 22, 2010, Finn, O.J. and J. Banchereau,

Guest Editors Inventions and Patents "SYNTHETIC MULTIPLE TANDEM REPEAT MUCIN-LIKE PEPTIDES, AND USE THEREOF", Inventors: Olivera J. Finn, Ph.D., Darrell Fontenot, Ph.D., Ronald Montelaro, Ph.D., University of Pittsburgh. Patent issued 1998. "ANTICANCER VACCINE AND DIAGNOSTIC METHODS", Inventors: Olivera J. Finn, Ph.D., Henry Kao, Ph.D., University of Pittsburgh, Donald Hunt, Ph.D., University of Virginia. Patent issued 2010. “THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN”, Inventors: Olivera J. Finn, Ph.D., University of Pittsburgh, Nehad M. Alajez, Ph.D., Ontario Cancer Institute, Mark Alter, Ph.D., Columbia University, Jan Schmielau, Ph.D., Lübeck University. Patent issued 2010. “CYCLIN B1 PEPTIDES AS CANCER VACCINES,” Inventors: Olivera J. Finn, Ph.D. and Laura Vella, University of Pittsburgh. Patent filed August 2008.